<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-055349</identifier>
<setSpec>0301-0546</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Monoclonal antibodies in Pediatrics: use in prevention and treatment</dc:title>
<dc:description xml:lang="en">An update is provided on monoclonal antibodies (MAbs): concept, production, indications for the diagnosis and treatment of neoplastic diseases and autoimmune disorders, prevention of transplant rejection, and treatment of allergic diseases, autoimmune disease and other noninflammatory disorders such as coronary disease. Mention is also made of MAb use in the prevention of respiratory syncytial virus (RSV) infection.         A more extensive account is provided of the use of MAb in B cell lymphomas (anti-CD20) and T cell leukemias (anti-IL-2 R). Likewise, mention is made of the use of MAbs in autoimmune disorders, such as anti-TNF-alfa in application to chronic arthritis, Crohn's disease and psoriasis, anti-C5 in the treatment of chronic arthritis, uveitis, systemic lupus erythematosus, and autoimmune hemolytic anemia. Anti-KT 3 MAb is used to treat acute rejection and graft versus host disease, while anti-IL-2 R alfa and anti-IL-2 R gamma are used for the prevention of acute transplant rejection. Anti-IgE MAb (omalizumab) is used to treat asthma and allergic rhinitis refractory to other treatments. Anti-L5 (mepolizumab), anti-IL-4, anti-TNF and anti-inflammatory cytokine mediator MAbs all have indications in asthma and severe allergic rhinitis, and in intense atopic dermatitis refractory to other treatments. As to the MAbs used for the prevention of RSV infection, mention is made of anti-epitope A of the F protein of the virus</dc:description>
<dc:creator>Martin-Mateos, MA</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Se expone una actualización sobre los anticuerpos monoclonales (AcM): concepto, producción, indicaciones de uso para diagnóstico y tratamiento de enfermedades neoplásicas, enfermedades autoinmunes, prevención del rechazo de trasplantes, tratamiento de enfermedades alérgicas, enfermedades autoinmunes y otras enfermedades no inflamatorias como la enfermedad coronaria. También para la profilaxis de la infección por el VRS.         Se trata con mas extensión el uso de AcM en linfoma de células B( anti-CD20), leucemia de células T ( anti-R IL2.El uso de AcM en enfermedades autoinmunes: anti-FNT-alfa en la Artritis crónica, Enfermedad de Crohn y Psoriasis, AcM anti-C5 en el tratamiento de la Artritis crónica, Uveítis, Lupus Eritematoso Sistémico y Anemia hemolítica autoinmune. AcM anti-KT 3 en el tratamiento del rechazo agudo y de la Enfermedad injerto contra huésped; AcM anti-R IL2 alfa y AcM anti-R IL2 gamma en la profilaxis del rechazo agudo de los trasplantes. AcM anti-IgE (Omalizumab) en el tratamiento del asma y rinitis alérgicas refractarias a otros tratamientos; AcM anti-L5 (Mepolizumab), AcM anti-IL4, AcM anti-FNT y AcM anti-mediadores de citocinas inflamatorias, todos ellos con indicaciones en asma y rinitis alérgica grave y en dermatitis atópica intensa refractaria a otros tratamientos. AcM usados en profilaxis de la infección por Virus Respiratorio Sincitial, anti-epítopo A de la proteína F del VRS</dc:description>
<dc:source>Allergol Immunopathol (Madr);35(4): 145-150, jul. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-055349</dc:identifier>
<dc:title xml:lang="es">Anticuerpos monoclonales en pediatría: uso para profilaxis y tratamiento</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d6235^s22054</dc:subject>
<dc:subject>^d1333^s22067</dc:subject>
<dc:subject>^d9562^s22067</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d7145^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200707</dc:date>
</metadata>
</record>
</ibecs-document>
